Author

Christopher R. Rowland

Observed name: Chris Rowland

Institution: TG Therapeutics, Inc. (United States)

Observed institutions: Duke University, Washington University in St. Louis, Duke Medical Center, Shriners Hospitals for Children - St. Louis, TG Therapeutics, Inc. (United States)

ORCID: 0000-0003-0228-4054

Observed ORCID: 0000-0003-0228-4054

OpenAlex ID: A5078925187

Chondrogenesis of Adult Stem Cells from Adipose Tissue and Bone Marrow: Induction by Growth Factors and Cartilage-Derived Matrix

2009 · Brian O. Diekman, Christopher R. Rowland, et al. · Tissue Engineering Part A · 270

The effects of crosslinking of scaffolds engineered from cartilage ECM on the chondrogenic differentiation of MSCs

2013 · Christopher R. Rowland, Donald P. Lennon, et al. · Biomaterials · 193

Fabrication of anatomically-shaped cartilage constructs using decellularized cartilage-derived matrix scaffolds

2016 · Christopher R. Rowland, Lina A. Colucci, et al. · Biomaterials · 124

Regulation of decellularized tissue remodeling via scaffold-mediated lentiviral delivery in anatomically-shaped osteochondral constructs

2018 · Christopher R. Rowland, Katherine A. Glass, et al. · Biomaterials · 93

Meniscus-Derived Matrix Scaffolds Promote the Integrative Repair of Meniscal Defects

2019 · Jacob C. Ruprecht, Taylor D. Waanders, et al. · Scientific Reports · 42

Factors Influencing the Long-Term Behavior of Extracellular Matrix-Derived Scaffolds for Musculoskeletal Soft Tissue Repair

2012 · Christopher R. Rowland, Dianne Little, et al. · Journal of Long-Term Effects of Medical Implants · 17

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

2023 · Brian T. Hill, Shuo Ma, et al. · Blood Advances · 14

Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study

2026 · Bruce A. C. Cree, Edward Fox, et al. · JAMA Neurology · 10

Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma

2023 · Danielle S. Wallace, Chris Rowland, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 3

Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial

2021 · Javier Pinilla Ibarz, Wojciech Jurczak, et al. · Blood · 2

Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates From the ENHANCE Study (P9-19.002)

2026 · Barry Singer, Craig Herrman, et al. · Neurology

No Association Between Decreases in Serum Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) and Serious Infections (SI) with Long-term Ublituximab (UBL) Treatment in Patients with Relapsing Multiple Sclerosis (RMS) (P7-1.017)

2025 · Lawrence Steinman, Edward Fox, et al. · Neurology

502. Biomaterial-Mediated Lentiviral Delivery of Anti-Inflammatory Genes in Cartilage-Derived Matrix Hemispheres

2016 · Katherine A. Glass, Christopher R. Rowland, et al. · Molecular Therapy

Development of Cartilage-Derived Matrix Scaffolds via Crosslinking, Decellularization, and Ice-Templating

2015 · Christopher R. Rowland · DukeSpace (Duke University)

Works count: 14

Citation count: 768

H-index: 8

I10-index: 8